Teleflex Incorporated TFX
Composite 38/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 17/100 — a strong mark against it.
Momentum ranks 60/100 — a slight point in its favour.
Growth ranks 17/100 — a strong mark against it. Quality ranks 32/100 — a moderate mark against it. Valuation ranks 37/100 — a moderate mark against it.
What the company does Teleflex designs and manufactures single-use medical devices for critical care and surgical procedures, including vascular catheters, hemostatic products, and interventional devices under brands like Arrow and QuikClot.
Key financials Revenue grew 32.3% while EPS surged 64.1%, but net margin remains negative at -47.4% despite a strong gross margin of 55.3%. ROE is 0.0%, ROA is 2.3%, and ROCE is -3.7%, with a high debt/equity of 0.89 and interest coverage of -1.97.
Stock health Momentum is mixed: 6m +26.30%, 12m +15.87%, but 3m -0.49% and down -5.03% from its 52-week high. RSI(14) is neutral at 50.20. Sideravia scores the stock as “Poor quality, fairly valued,” with overall 40.5/100.
Price vs fair value The stock trades at a **discount** of 106.60% versus our fair-value estimate of 273.35 and a **discount** of 11.45% versus the analyst 12-month target of 147.45. - Fair-value gap reflects high uncertainty in net margins (-47.4%) and weak profitability metrics (ROE 0.0%, ROCE -3.7%). - Analyst target implies +11.45% upside from current 132.30, but only 11 analysts cover the name (low conviction). - Recent DexCom earnings beat (DXCM) may have shifted investor focus away from capital-intensive medtech names like TFX.
Looking forward Forward P/E of 20.00 and PEG of 0.16 suggest valuation is not extreme, but FCF yield is negative (-0.1%) and payout ratio is unsustainably high at 2266.7%. Watch for stabilization in net margins and execution on interventional product growth.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.